MedTrace Logo

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

NCT04695431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2022-01-10

No results posted yet for this study

Summary

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

Conditions

Sponsors & Collaborators

  • Analysis Group, Inc.

    collaborator INDUSTRY

  • Blueprint Medicines Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2021-10-04
Completion
2021-10-04

Countries

  • United States
  • Austria
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04695431 on ClinicalTrials.gov